Skip to main navigation
Skip to search
Skip to main content
WashU Research Profiles Home
Help & FAQ
Link opens in a new tab
Search content at WashU Research Profiles
Home
Profiles
Research units
Research output
Treatment of CNS sarcoidosis with infliximab and mycophenolate mofetil
Michael Moravan
, Benjamin M. Segal
Division of Clinical Research
Research output
:
Contribution to journal
›
Article
›
peer-review
138
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Treatment of CNS sarcoidosis with infliximab and mycophenolate mofetil'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Infliximab
100%
Mycophenolate Mofetil
100%
CNS Sarcoidosis
100%
Sarcoidosis
33%
Neurosarcoidosis
33%
CNS Involvement
33%
Tumor Necrosis Factor-α
16%
Treatment Response
16%
Neutralizing Antibodies
16%
Neurological Examination
16%
Therapeutic Approaches
16%
Symptomatic Improvement
16%
Cord
16%
Lesion Size
16%
Biopsy-proven
16%
Dural
16%
Combination Treatment
16%
Single Lesion
16%
Treatment Failure
16%
Intraparenchymal
16%
Motor Coordination
16%
Neuropathic Pain
16%
Sensory-motor
16%
Seizure Activity
16%
Leptomeningeal
16%
Serious Adverse Effects
16%
Headache Pain
16%
Positive Treatment
16%
Promising Therapeutics
16%
MRI Scanning
16%
Antiproliferative
16%
Gadolinium Enhancement
16%
Infliximab Therapy
16%
Pharmacology, Toxicology and Pharmaceutical Science
Infliximab
100%
Sarcoidosis
100%
Mycophenolate Mofetil
100%
Neurosarcoidosis
28%
Tumor Necrosis Factor
14%
Neutralizing Antibody
14%
Headache
14%
Immunosuppressive Agent
14%
Neuropathic Pain
14%
Gadolinium
14%
Steroids
14%
Adverse Effect
14%